Current Cancer Drug Targets

Editor-in-Chief:

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
USA

Back

Become EABM
Become Reviewer

Selectively Replicating Adenoviruses for Oncolytic Therapy

Volume:1   Issue: 2
Pp: 85-107
Tack-Kee Laurent Yoon, Toshiaki Shichinohe, Sylvie Laquerre and Noriyuki Kasahara
DOI: 10.2174/1568009013334223

Selective Destruction of Tumor Cells through Specific Inhibition of Products Resulting from Chromosomal Translocations

Volume:1   Issue: 2
Pp: 109-119
A. Rodriguez-Garcia, M. Sanchez-Martin, J. Perez-Losada, P. A. Perez-Mancera, A. Sagrera-Aparisi, N. Gutierrez-Cianca, C. Cobaleda and I. Sanchez-Garcia
DOI: 10.2174/1568009013334214

Mutant Cell Surface Receptors as Targets for Individualized Cancer Diagnosis and Therapy

Volume:1   Issue: 2
Pp: 121-128
Karl-Friedrich Becker and Heinz Hofler
DOI: 10.2174/1568009013334205

Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents

Volume:1   Issue: 2
Pp: 129-140
Sutapa Ghosh, Xing-Ping Liu, Yaguo Zheng and Fatih M. Uckun
DOI: 10.2174/1568009013334188

Thymidine Phosphorylase: A Two-Face Janus in Anticancer Chemotherapy

Volume:1   Issue: 2
Pp: 141-153
F. Focher and S. Spadari
DOI: 10.2174/1568009013334232

Microarrays: Spotlight on Gene Function and Pharmacogenomics

Volume:1   Issue: 2
Pp: 155-175
M. Nees and C. D. Woodworth
DOI: 10.2174/1568009013334197